Quick Answer
Ensysce Biosciences, Inc. reported Total Revenue of $5.07 million for fiscal year 2025.
Ensysce Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.07M -2.8% |
$5.21M +133.6% |
$2.23M -11.6% |
$2.52M -28.5% |
$3.53M | — |
| Revenue (ASC 606) | $5.07M -2.8% |
$5.21M +133.6% |
$2.23M -11.6% |
$2.52M -28.5% |
$3.53M | — |
| Net Income | — | — | — | — | — | $2.40M +557.1% |
| Diluted EPS | -$3.98 +65.2% |
-$11.45 +83.7% |
-$70.40 +49.5% |
-$139.42 -9320.3% |
-$1.48 | $0.00 |
| Total Assets | $7.45M +33.1% |
$5.60M +106.7% |
$2.71M -54.0% |
$5.89M -64.2% |
$16.42M +4566.6% |
$351.8K -99.8% |
| Cash and Equivalents | $4.31M +23.1% |
$3.50M +211.7% |
$1.12M -64.3% |
$3.15M -74.3% |
$12.26M +6215.1% |
$194.2K |
| Stockholders Equity | $3.21M -13.3% |
$3.71M +1248.6% |
-$322.9K +91.3% |
-$3.71M +52.9% |
-$7.88M -22.3% |
-$6.44M -228.8% |
| R&D Expense | $10.38M +43.7% |
$7.22M -4.9% |
$7.59M -61.7% |
$19.84M +322.9% |
$4.69M +6.8% |
$4.39M |
| Operating Income | -$10.24M -52.2% |
-$6.73M +37.2% |
-$10.72M +55.8% |
-$24.22M -21.9% |
-$19.87M -1131.7% |
-$1.61M +51.5% |
| Shares Outstanding | 4.57M +237.4% |
1.36M +546.4% |
209,739 -60.8% |
534,490 +71.9% |
310,963 -98.0% |
15.77M +147.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $493.1K | -85.6% | -64.0% |
| Revenue (ASC 606) | September 30, 2025 | $493.1K | -85.6% | -64.0% |
| Net Income | September 30, 2021 | -$17.16M | -1192.9% | -1734.6% |
| Diluted EPS | September 30, 2025 | -$1.29 | -229.0% | -63.3% |
| Total Assets | September 30, 2025 | $3.18M | -66.1% | -43.0% |
| Cash and Equivalents | September 30, 2025 | $1.67M | -59.7% | -24.3% |
| Stockholders Equity | September 30, 2025 | $1.20M | -82.6% | -64.5% |
| R&D Expense | September 30, 2025 | $2.95M | +74.8% | +53.6% |
| Operating Income | September 30, 2025 | -$3.74M | -680.2% | -113.7% |
| Shares Outstanding | September 30, 2025 | 3.18M | -77.1% | +32.9% |
- Ensysce Biosciences, Inc. reported Total Revenue of $5.07 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed a decrease of -2.8% in Total Revenue compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Revenue (ASC 606) of $5.07 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed a decrease of -2.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Net Income of $2.40 million for fiscal year 2020.
- Ensysce Biosciences, Inc. showed an increase of +557.1% in Net Income compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Diluted EPS of $3.98 per share (loss) for fiscal year 2025.
- Ensysce Biosciences, Inc. showed an increase of +65.2% in Diluted EPS compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Total Assets of $7.45 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed an increase of +33.1% in Total Assets compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Cash and Equivalents of $4.31 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed an increase of +23.1% in Cash and Equivalents compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Stockholders Equity of $3.21 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed a decrease of -13.3% in Stockholders Equity compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported R&D Expense of $10.38 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed an increase of +43.7% in R&D Expense compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Operating Income of -$10.24 million for fiscal year 2025.
- Ensysce Biosciences, Inc. showed a decrease of -52.2% in Operating Income compared to the prior fiscal year.
- Ensysce Biosciences, Inc. reported Shares Outstanding of 4.57 million shares for fiscal year 2025.
- Ensysce Biosciences, Inc. showed an increase of +237.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: